A-319 has the same mechanism of action as that of blinatumomab, and may benefit B-NHL patients. A-319 was well tolerated in relapsed/refractory B-NHL. A-319 at the dose level of 1. 2 ug/kg/day showed encouraging disease control and warranted further clinical investigation.